Regenxbio (RGNX) Cash & Equivalents (2014 - 2026)

Regenxbio's Cash & Equivalents history runs 12 years deep, the most recent figure standing at $34.5 million for Q4 2025.

• In Q4 2025, Cash & Equivalents fell 40.09% year-over-year to $34.5 million; the TTM figure through Dec 2025 stood at $34.5 million (down 40.09% YoY), while the FY2025 annual figure was $34.5 million, down 40.09% from the prior year.
• Cash & Equivalents for Q4 2025 stood at $34.5 million, down from $58.8 million in the prior quarter.
• The five-year high for Cash & Equivalents was $345.2 million in Q4 2021, with the low at $34.5 million in Q4 2025.
• The 5-year median for Cash & Equivalents is $88.3 million (2022), against an average of $123.2 million.
• The sharpest annual moves came in 2021 and 2022: Cash & Equivalents jumped 319.94% in 2021, then plunged 71.91% in 2022.
• Regenxbio's Cash & Equivalents stood at $345.2 million in 2021, then slumped by 71.91% to $97.0 million in 2022, then tumbled by 64.39% to $34.5 million in 2023, then surged by 66.64% to $57.5 million in 2024, then tumbled by 40.09% to $34.5 million in 2025.
• Business Quant data shows RGNX's Cash & Equivalents at $34.5 million in Q4 2025, $58.8 million in Q3 2025, and $79.6 million in Q2 2025.